The mechanisms involved in mycosis fungoides, and Sezary Syndrome progression are largely unknown. Over the last decade the interest in immune system contrast of neoplasm has grown owing to the introduction of immunotherapy. PD-1 and its ligand (PD-L1) are the target of several immunotherapy treatment. In the literature reports on the expression of PD-1 and PD-L1 have provided contrasting results.
Pileri, A., Tabanelli, V., Fuligni, F., Agostinelli, C., Guglielmo, A., Sabattini, E., et al. (2022). PD-1 and PD-L1 expression in mycosis fungoides and Sézary Syndrome. ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 157(4), 355-362 [10.23736/S2784-8671.22.07275-9].
PD-1 and PD-L1 expression in mycosis fungoides and Sézary Syndrome
Pileri, Alessandro;Tabanelli, Valentina;Fuligni, Fabio;Agostinelli, Claudio;Guglielmo, Alba;Sabattini, Elena;Pileri, Stefano A;
2022
Abstract
The mechanisms involved in mycosis fungoides, and Sezary Syndrome progression are largely unknown. Over the last decade the interest in immune system contrast of neoplasm has grown owing to the introduction of immunotherapy. PD-1 and its ligand (PD-L1) are the target of several immunotherapy treatment. In the literature reports on the expression of PD-1 and PD-L1 have provided contrasting results.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
